

Regd. Office :
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

October 22, 2015

Bombay stock Exchange Limited
1st Floor, P.J. Towers
Dalal Street
MUMBAI – 400 001

Kind Attn.: Mr. Kapoor
Mr. Goopalkrishnan

National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor
Plot No. C/1, G Block
Bandra-Kurla Complex
Bandra – (East)
Mumbai – 400 051

Kind Attn.: Famroze Pochara
Asst. Vice President

Dear Sir

Re.: Press Release

We are forwarding you herewith copy of press release proposed to be published in the newspapers in the matter of Un-audited financial results for the quarter/half year ended on September 30, 2015 the same may please receive in order.

Thanking you

Yours faithfully

For CADILA HEALTHCARE LIMITED



UPEN H. SHAH
COMPANY SECRETARY

Encl.: As above

Zydus Cadila's Net Profit up by 41% in Q2

Ahmedabad, October 22, 2015

For the second quarter ended September 30, 2015, Zydus Cadila reported Total Operating Income of Rs. 2460 crores, up by 17% from Rs. 2108 crores in the corresponding quarter of the previous year on a consolidated basis. Net Profit for the same period was up by 41% from Rs. 278 crores to Rs. 391 crores.

During the quarter, the company's business in the US posted sales of Rs. 1004 crores registering a growth of 25%. The company received approval for 1 new product from the USFDA and 2 products were launched in the US market.

In the domestic formulations market, the company launched 13 new products, including line extensions, of which 4 products were the first to be launched in India. In Mexico, the company launched 2 new products during the quarter, taking the cumulative launches to over 15 and received the regulatory approval for 6 more dossiers, taking the cumulative number of approvals to over 30.
